Clinical Trials Logo

Filter by:
NCT ID: NCT03737591 Recruiting - Colorectal Cancer Clinical Trials

The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas

Start date: May 1, 2018
Study type: Observational

This is a prospective, multicenter, clinical study. This study is to evaluate the sensitivity of plasma ctDNA methylation haplotypes in detecting colorectal cancer, adenoma and the specificity in healthy individuals.

NCT ID: NCT03737539 Recruiting - Colorectal Cancer Clinical Trials

Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Stage II-III Colorectal Cancer After Radical Resection

Start date: September 1, 2018
Study type: Observational [Patient Registry]

This is a prospective, multicenter, observational, single-blinded controlled study. Dynamic monitoring of patients with stage II-III colorectal cancer was performed using the previously established colorectal tumor-specific plasma ctDNA methylation markers (diagnostic model established by next-generation sequencing of 2181 gene loci methylation). The methylation marker had a sensitivity of 93% in colorectal cancer patients with a specificity of 99% in healthy individuals. Dynamic monitoring of high-throughput next-generation sequencing of plasma ctDNA methylation before and after treatment and at regular follow-up in patients with colorectal cancer after radical resection of stage II-III colorectal cancer, to explore the predictive effect of postoperative plasma ctDNA methylation on postoperative recurrence and whether dynamic monitoring of postoperative ctDNA methylation could be earlier than imaging examination to indicate tumor recurrence.

NCT ID: NCT03737513 Active, not recruiting - Rhabdomyolysis Clinical Trials

Exercise-induced Collective Rhabdomyolysis

Start date: September 9, 2018
Study type: Observational

Rhabdomyolysis, which is a characteristic occurrence in associated with muscle cell necrosis, develops due to various causes. We herein report a rare case of collective rhabdomyolysis after high intensity resistance training, including 35 teenagers,in which markedly elevated levels of serum creatine kinase (CK) and serum myoglobin were observed. This high intensity resistance trainings is a part of Military Training(MT),which all the middle school students must finish before admission。

NCT ID: NCT03737175 Recruiting - Carotid Stenosis Clinical Trials

Endarterectomy vs Stenting in Chinese Asymptomatic Carotid Stenosis Patients

Start date: March 30, 2018
Phase: N/A
Study type: Interventional

Endarterectomy vs Stenting Asymptomatic Carotid stenosis patients to verify the efficacy and safety.

NCT ID: NCT03737162 Recruiting - Clinical trials for Subclavian Occlusion

Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions

Start date: April 2, 2018
Phase: N/A
Study type: Interventional

Bare-metal stent vs Covered stent with subclavian occlusive lesions to verify the efficacy and safety.Study Design are prospective, multiple center, randomized, open, positive controlled, non-inferiority trail.Case total numbers enrollment predict 408 cases,each group 204 cases.Follow up period for 1 years.

NCT ID: NCT03736889 Recruiting - Clinical trials for MSI-H/dMMR Solid Tumors

Tislelizumab (Anti-PD-1 Antibody) in MSI-H or dMMR Solid Tumors

Start date: September 19, 2018
Phase: Phase 2
Study type: Interventional

In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, patients with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317). Efficacy and safety will be assessed. A short description of the clinical study, including a brief statement of the clinical study's hypothesis, written in language intended for the lay public.

NCT ID: NCT03736863 Not yet recruiting - Esophageal Cancer Clinical Trials

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Start date: December 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib as second-line treatment of advanced esophageal squamous cell.

NCT ID: NCT03736850 Recruiting - Clinical trials for Locally Advanced or Metastatic Solid Tumors

A Phase I Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: October 19, 2018
Phase: Phase 1
Study type: Interventional

This is a multicenter, open label, sequential-cohort, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006 and to establish the Maximum Tolerated Dose (MTD), if any, Recommended Phase II Doses (RP2Ds) and regimen of CS3006. The study is composed of two parts: Part 1 for dose escalation and Part 2 for dose expansion.

NCT ID: NCT03736837 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Start date: November 9, 2018
Phase: N/A
Study type: Interventional

Evaluate the Efficacy and Safety of Anlotinib Plus Icotinib as the first-line Treatment in Patients With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer.

NCT ID: NCT03736824 Recruiting - Malignancy Clinical Trials

Correlation of Endoscopic Findings and Symptoms in Patients Undergoing the First Upper Gastrointestinal Endoscopy

Start date: January 1, 2018
Study type: Observational

Endoscopy is the best means of finding early stage of upper gastrointestinal diseases, especially early cancer and benign ulcers. Currently, most people still undergo upper gastrointestinal endoscopy due to discomfort, rather than a regular physical examination at a certain age. This study prospectively investigated the reason for undergoing the first upper gastrointestinal endoscopy in patients and found the correlation of endoscopic findings and symptoms.